Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Increasing benefit seen in novel drug that treats Gleevec resistance

20.04.2005


An investigational drug is producing powerful responses in patients resistant to Gleevec, the targeted therapy that helps most people diagnosed with chronic myeloid leukemia (CML), an international research team headed by investigators at The University of Texas M. D. Anderson Cancer Center is reporting.



The drug, AMN107, is showing an increasingly strong benefit as doses are being steadily raised, say the researchers, who presented their latest analysis at the annual meeting of the American Association for Cancer Research.

In an ongoing study that has enrolled more than 100 patients, over 90 percent of those with the earlier stage "chronic" phase of CML have had a hematologic response, meaning their blood counts have returned to normal, says Francis Giles, M.D., a professor of medicine in the Department of Leukemia at M. D. Anderson. Additionally, more than 70 percent of patients with the advanced "accelerated" and terminal "blast" stages of the disease have similarly benefited, and the number of complete molecular remissions in patients also is steadily increasing, he says.


Giles can offer only estimates of response because he says that this study employs a new model of clinical trial design in which patients are continuously being given higher doses of the drug. "So the results change daily as patients fare increasingly better on higher doses," he says. "We are seeing benefit at lower doses that will only be fully quantifiable when all patients are on the maximal safe dose - a dose which we have not yet defined."

Clear activity was seen at the very first dose of 50 milligrams offered to the first patients who enrolled in May, 2004, Giles says. "This week everyone is being moved to the latest ceiling, which is 400 milligrams twice a day, and based on its safety and effectiveness, I believe we will soon move to 600 milligrams twice a day.

"If I had to guess, I would think the overall response rate across the whole population will be well over 75 percent," he says. Only within the last month have chronic phase patients been allowed into the study, and Giles estimates response in those patients may reach close to 100 percent because their cancer has not yet had the chance to form new mutations that the drug cannot treat. For that same reason, some patients with more advanced cancer will not respond to the drug, Giles points out.

Despite what he calls very exciting results from the use of AMN107, he stresses that CML patients should not think that they need to switch to this experimental drug. "Gleevec is incredibly powerful and failures are very rare in early phase CML. It is very effective in the great majority of patients," he says. "We are focused on a minority of patients, less than 10 percent of chronic patients, who more than likely need some other form of intervention to give them a normal life span."

CML is caused by the errant swapping of genetic material in bone marrow stem cells that produces an abnormality called the Philadelphia chromosome. This chromosome contains a new fused-together gene, BCR-ABL, which produces an enzyme that switches on uncontrolled growth in the bone marrow cell. Gleevec binds to this Bcr-Abl enzyme, shutting down its activity, which often leads to death of the leukemia cell.

AMN107 is estimated to be up to 30 to 100 times more potent than Gleevec because it was designed to more efficiently bind to Bcr-Abl, including to mutated forms of the enzyme that can produce Gleevec resistance, Giles says.

But the drugs have not been compared head-to-head, so Giles says, "I can’t say that AMN107 is better than Gleevec."

Giles, however, is planning to open a clinical trial at M. D. Anderson this summer to test AMN107 as a "frontline" therapy - the first treatment given - in chronic phase CML patients. Another six clinical trials testing the drug in all three separate phases of CML, as well as in other leukemias in which Gleevec has shown some benefit, also are slated to open soon.

Giles suggests that in the future, both Gleevec and AMN107, as well as perhaps other new tailored agents, may all be used in treating CML, especially if these drugs show a synergistic effect.

M. D. Anderson enrolled patients in the study, as did researchers at the University of Frankfurt in Germany. Giles presented first results of the therapy in fewer patients last December at the annual meeting of the American Society of Hematology.

Nancy Jensen | EurekAlert!
Further information:
http://www.mdanderson.org

More articles from Health and Medicine:

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>